- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Authors
Latest:
Impact of Advance Care Planning Consults on Advance Directives CompletionImplementing advance care planning consults can increase advance directive completion rates. The authors demonstrate the impact of consults on completed advance directives in the medical record.
Latest:
Cost-effectiveness of a 3-Year Tele-Messaging Intervention for Positive Airway Pressure UseLong-term tele-messaging was more effective than no messaging and short-term messaging for positive airway pressure use, and it was highly likely to be cost-effective with an acceptable willingness-to-pay threshold.
Latest:
Cost-effectiveness of a 3-Year Tele-Messaging Intervention for Positive Airway Pressure UseLong-term tele-messaging was more effective than no messaging and short-term messaging for positive airway pressure use, and it was highly likely to be cost-effective with an acceptable willingness-to-pay threshold.
Latest:
Contributor: After COVID-19, an AI-Driven Path to Risk-Adjusted Value-Based CareArtificial intelligence (AI) could help drive accurate and effective risk adjustment in value-based care plans.
Latest:
Eliminating Defects in Value: Turnaround of an MSSP ACOA health system transformational leadership framework and management system made visible and eliminated defects in value and was associated with reduced annual Medicare expenditures and increased quality between 2017 and 2020.
Latest:
TrumpRx Effects on Medicaid Rebates, Cost-Shifting, and Value-Based Drug Pricing: Robert AndrewsRobert Andrews, CEO of the Health Transformation Alliance, addresses Medicaid rebates, cost-shifting concerns, and value-based pricing trends.
Latest:
Identifying Complex Patients Using Adjusted Clinical Groups Risk Stratification ToolIn this study, the authors developed a method for use in primary care to identify a group of patients with complex care needs using Aggregated Diagnosis Groups.
Latest:
Combatting COVID-19 With Real-World EvidenceA vaccine isn’t the panacea many assume it will be. Even when it becomes available, the virus won’t go away. Real world evidence will be needed to guide decision making.
Latest:
Provider Barriers in Uptake of Biosimilars: Case Study on FilgrastimPrevious studies have found modest uptake of biosimilars in both commercial and Medicare populations. This study finds that the uptake varies between the rural and urban provider settings.
Latest:
Institutional Practices for Charitable Medication Access for Uninsured PatientsAnalysis of a patient sample enrolled in charitable care at an academic medical center revealed that chronic medications were variably filled at a significant cost.
Latest:
Timely Preterm-Birth Prediction Among Pregnant Women in Medicaid Without Preterm-Birth HistoryA novel prediction model is developed that accurately predicts preterm birth in a timely manner among pregnant women in Medicaid without preterm-birth history.
Latest:
Contributor: When AI Sees, Yet Cannot Judge—Why Health Care Must Remain Human-LedAlthough artificial intelligence (AI) is quickly becoming a tool used in health care, the human aspect of health care is still necessary for continued care.
Latest:
Real-World Value of Direct-Acting Antivirals for Hepatitis C at Kaiser Permanente Southern CaliforniaThis analysis demonstrates value and innovation of direct-acting antivirals for the treatment of chronic hepatitis C in the US Kaiser Permanente health system.
Latest:
People Experiencing Homelessness in Miami: Insurance Enrollment Rates, Hypertension TrendsPeople experiencing homelessness face significant barriers to health care access, leading to higher rates of hypertension even among those with health insurance.
Latest:
High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight ManagementThis Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.
Latest:
Better Together? Costs of First-line Chemoimmunotherapy for Advanced Non–Small Cell Lung CancerCompared with first-line immunotherapy or chemotherapy alone, combination chemoimmunotherapy for advanced/metastatic non–small cell lung cancer has significantly higher antineoplastic drug and associated medical costs.
Latest:
Looking Toward the Future: Management of C. Diff InfectionClosing out their discussion on recurrent clostridium difficile infection management, experts share closing thoughts and hopes for the future.
Latest:
Baffled by NAFLD: The Horse Might Be Out of the Barn but Should Not Take Us for a RideAs awareness of nonalcoholic fatty liver disease (NAFLD) rises, it is essential to develop and implement a rigorously determined approach to identify patients who will, or will not, benefit from diagnostic evaluation.
Latest:
Overhauling Quality Measurement in the US: Measure What MattersAs the US charts its course through the next political era, it is crucial that we boldly allocate resources and prioritize what truly impacts patients. When faced with complexity, feasibility concerns, or entrenched norms, we must proclaim: “It’s the outcomes, stupid.”
Latest:
Future Treatments for Dry Eye Can Prioritize Anti-Inflammatory Route: Nicole Bajic, MDWith inflammation being the cause of dry eye in many cases, future treatment will likely target this aspect of dry eye.
Latest:
Contributor: Steps Health Professionals Can Take to Reduce Inequality in Health OutcomesJason Shafrin, PhD, serves as the vice president of Health Economics at PRECISIONheor, and Meena Venkatachalam, MSc, is the senior director of Health Economics at PRECISIONheor.
Latest:
Impact of the COVID-19 Pandemic on Regular Emergency Department UsersRegular users of the emergency department (ED) transiently reduced ED visits when faced with ED access barriers during the COVID-19 pandemic.
Latest:
Addressing the Psychosocial Impacts of Inflammatory Skin Conditions in Patient CareLauren Miller, PA-C, kicked off the inaugural 2023 Inflammatory Disease Summit by discussing the psychosocial impacts related to atopic dermatitis, psoriasis, and hidradenitis suppurativa.
Latest:
Inpatient Opioid Receipt and Care Experiences for Vaginal DeliveryThe objective of this study was to examine the relationship between inpatient opioid receipt and care experiences of women hospitalized for vaginal delivery.
Latest:
Long-Term Health Care Costs Following COVID-19: Implications for Pandemic PreparednessA difference-in-differences analysis of health care claims data evaluated excess health care costs in the 12 months following COVID-19 diagnosis among the general and older adult populations.
Latest:
Post-SNF Outcomes and Cost Comparison: Medicare Advantage vs Traditional MedicarePatients enrolled in Medicare Advantage had better outcomes and lower cost following skilled nursing facility (SNF) discharge than patients enrolled in traditional fee-for-service Medicare.
Latest:
Breaking Barriers, Fostering Collaboration at AACR Annual Meeting 2025Program chairs Lillian L. Siu, MD, FAACR, and Matthew G. Vander Heiden, MD, PhD, highlight the cross-disciplinary approach to cancer research and innovation being taken at this year's American Association for Cancer Research (AACR) Annual Meeting.
Latest:
US Shouldn't Back Out of Funding HIV Research After Huge Strides Made: Patrick Sullivan, DVM, PhDThe government should focus on keeping up the funding for HIV to continue to innovate in this space, potentially eliminating the virus altogether.
Latest:
Empiric Segmentation of High-risk Patients: A Structured Literature ReviewData-driven segmentation of high-risk patient populations may inform health system interventions, but results are dependent on the data sources and methods applied.
Latest:
Integrating CAR T-Cell Therapy and Bispecific Antibodies Into Hematologic Malignancy Care: Anita D’Souza, MDChimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies are transforming multiple myeloma care, with earlier use, expanded community access, and outpatient delivery models offering opportunities to improve value, safety, and equity in treatment.
